Cabozantinib is the active ingredient in two of Exelixis' three approved drugs (Cabometyx and Cometriq) and its strongest US patent covering cabozantinib’s composition of matter expires in 2030.
Today, a brief rundown of news from GSK and Amgen, as well as updates from Roche, AbbVie, and Marinus Pharmaceuticals that you may have missed. GSK is making its largest investment in U.S.
But first: a quick definition. Why getting up to speed on card payments is essential for SMEs – In this piece, in association with Boost Capital, we look at why card payment technology is crucial for ...
The One Direction star discovered he was dropped by his record label, Universal ... “Liam was battling a very significant drug addiction and his treatment, as those who knew him will attest ...
where we'll share with you the very best offers from around the web on some of our best-rated musical equipment. As the name suggests, we'll bring you a new batch of exciting discounts every week, so ...
Former President Donald Trump said anti-abortion supporters make up only "a very small percentage" of the country. Trump spoke on Fox News with a town hall of women about issues ranging from ...
It also has a very charming secret that will delight long-time fans. If you thought this Lego set could be purchased for less than $270 at one point, you'd be correct. Released in 2020 with a ...